Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
GuangYuYuan Chinese Herbal Medicine Co., Ltd. (600771.SS)
CNY15.30
+0.20 (+1.32%)
CN SHH Healthcare Drug Manufacturers - General
Address
Building A, 6th Floor 710065
Xi'an, CN
Xi'an, CN
CEO
Junbo Wang
Website
guangyuyuan.com
IPO
1996-11-05
ISIN CNE000000MY1
Description
GuangYuYuan Chinese Herbal Medicine Co., Ltd. specializes in the production and sale of traditional Chinese pharmaceutical goods. Their comprehensive range includes both classic and high-quality Chinese medicines, in addition to health-boosting wines. These remedies are available in diverse formats, such as pills, powders, tablets, hard capsules, granules, oral liquids, decoctions, and various wine preparations. The enterprise, which previously operated as Topsun Science And Technology Co Ltd., adopted its current name, GuangYuYuan Chinese Herbal Medicine Co., Ltd., in July 2013. Its primary operations are located in Xi'an, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY15.30
+0.20 (+1.32%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
7M
Beta
0.26
Float Shares
415.64M
Free Float %
84.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.39% | +0.79% | -9.13% | -14.29% | -21.17% | -15.29% | -29.59% | -62.14% | -28.60% | -11.71% | +876.47% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
15.30
DCF (Unlevered)
30.85
+101.6%
DCF (Levered)
12.17
-20.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
6.35
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
6 / 10
Developing
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - General: +6.6%+12.1% ★ Q1'26: +17.0% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%-13.3% Q1'26: +7.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+11.8% ★ Q1'26: +22.8% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+7.7% Q1'26: +15.4% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+4.6% Q1'26: +20.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%-2.3% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×0.41× ★ Q1'26: 0.14× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
428.44M
est: 666.00M (-35.7%)
|
936.99M
est: 1.36B (-31.0%)
|
1.17B
est: 1.74B (-32.7%)
|
1.62B
est: 1.98B (-18.1%)
|
1.22B
est: 1.97B (-38.2%)
|
1.11B
est: 2.43B (-54.3%)
|
854.22M
est: 891.09M (-4.1%)
|
1.13B
est: 1.27B (-10.6%)
|
1.28B
est: 1.35B (-4.6%)
|
1.22B
est: 1.75B (-30.2%)
|
1.37B
est: 1.43B (-4.1%)
|
1.66B
1.66B – 1.66B
+16.0% YoY
|
1.93B
1.93B – 1.93B
+16.4% YoY
|
| EBITDA |
12.89M
est: -36.62M (+135.2%)
|
185.90M
est: -74.62M (+349.1%)
|
285.15M
est: -95.45M (+398.7%)
|
484.00M
est: -108.62M (+545.6%)
|
206.53M
est: -108.32M (+290.7%)
|
47.90M
est: -133.62M (+135.8%)
|
-324.45M
est: -49.00M (-562.2%)
|
-187.97M
est: -69.56M (-170.2%)
|
152.46M
est: -74.01M (+306.0%)
|
133.41M
est: 876.17M (-84.8%)
|
153.50M
est: 714.95M (-78.5%)
|
829.10M
829.10M – 829.10M
+16.0% YoY
|
964.79M
964.79M – 964.79M
+16.4% YoY
|
| EBIT |
8.03M
est: -59.98M (+113.4%)
|
178.94M
est: -122.22M (+246.4%)
|
277.55M
est: -156.35M (+277.5%)
|
470.85M
est: -177.91M (+364.7%)
|
174.55M
est: -177.43M (+198.4%)
|
13.21M
est: -218.86M (+106.0%)
|
-362.84M
est: -80.26M (-352.1%)
|
-226.68M
est: -113.93M (-99.0%)
|
113.18M
est: -121.23M (+193.4%)
|
91.43M
est: 831.57M (-89.0%)
|
105.56M
est: 678.57M (-84.4%)
|
786.91M
786.91M – 786.91M
+16.0% YoY
|
915.68M
915.68M – 915.68M
+16.4% YoY
|
| Net Income |
2.03M
est: 95.73M (-97.9%)
|
122.81M
est: 350.99M (-65.0%)
|
236.80M
est: 205.63M (+15.2%)
|
374.11M
est: 386.45M (-3.2%)
|
130.07M
est: 521.17M (-75.0%)
|
32.00M
est: 670.08M (-95.2%)
|
-316.24M
est: -332.56M (+4.9%)
|
-250.02M
est: -407.01M (+38.6%)
|
90.08M
est: 109.20M (-17.5%)
|
74.45M
est: 150.33M (-50.5%)
|
63.04M
est: 121.24M (-48.0%)
|
150.33M
150.33M – 150.33M
+24.0% YoY
|
184.28M
184.28M – 184.28M
+22.6% YoY
|
| SGA |
288.01M
est: 465.33M (-38.1%)
|
520.56M
est: 948.12M (-45.1%)
|
627.97M
est: 1.21B (-48.2%)
|
721.65M
est: 1.38B (-47.7%)
|
643.89M
est: 1.38B (-53.2%)
|
656.40M
est: 1.70B (-61.3%)
|
863.76M
est: 622.60M (+38.7%)
|
879.55M
est: 883.84M (-0.5%)
|
733.26M
est: 940.44M (-22.0%)
|
661.63M
est: 1.15B (-42.7%)
|
542.65M
est: 941.93M (-42.4%)
|
1.09B
1.09B – 1.09B
+16.0% YoY
|
1.27B
1.27B – 1.27B
+16.4% YoY
|
| EPS |
0.01
est: 0.19 (-96.3%)
|
0.31
est: 0.71 (-55.6%)
|
0.48
est: 0.41 (+15.9%)
|
1.06
est: 0.78 (+36.1%)
|
0.27
est: 1.05 (-74.7%)
|
0.07
est: 1.35 (-95.2%)
|
-0.65
est: -0.67 (+3.6%)
|
-0.51
est: -0.82 (+37.8%)
|
0.18
est: 0.22 (-18.2%)
|
0.15
est: 0.31 (-51.6%)
|
0.13
est: 0.25 (-48.0%)
|
0.31
0.31 – 0.31
+24.0% YoY
|
0.38
0.38 – 0.38
+22.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-25 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-20 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-14 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
278.57M
OE per share TTM
0.57
Owner's Yield
3.74%
Maintenance CapEx ratio
1,360.91%
Maint CapEx / Avg PPE
60.6%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 17 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 282.0K | 0.06% |
| 2 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 93.3K | 0.29% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 53.7K | 0.39% |
| 4 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 18.2K | 0.26% |
| 5 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 8.0K | 0.48% |
| 6 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 895.7K | 0.06% |
| 7 | Vanguard Total World Stock ETF VT | 0.00% | 217.9K | 0.06% |
| 8 | Vanguard ESG International Stock ETF VSGX | 0.00% | 15.1K | 0.10% |
| 9 | Vanguard Total International Stock ETF VXUS | 0.00% | 1.04M | 0.05% |
| 10 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 16.3K | 0.28% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
58.3K
Shares Outstanding
489.49M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hong Yu Lu | Vice President | — | male |
| Junbo Wang | Chief Financial Officer & Vice President | — | male |
| Li Qiao | Deputy Director of the Board Office & Securities Affairs Representative | — | — |
| Orchid Willow | Vice President | — | female |
| Shoujun Fu | Accounting Supervisor | — | — |
| Yan Ren | Vice President | — | male |
| Yun Tang | VP & Board Secretary | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600771.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
